trading halt, page-21

applera settlement ! I'm not sure where 'Kacy' gets that information from, when according to recent financials GTG is certainly NOT short of cash.

Likewise. speculation as to what Applera paid for a licence and comparing this to Genzyme - who you suggest must be 'kicking themselves', is ludicrous.

Firstly, the complexity of the 'non coding patents' and how they are applied to commercial applications is exactly that - COMPLEX.

There are so many variables that would effect the final settlement amount, that a comparison of Genzyme to Applera is erroneous and like trying to compare Apple to Microsift.

What one company requires a licence for may differ greatly from the next, as would the issues of exclusivity, product development, testing applications and commercial opportunities etc.

Given the limited details re Applera settlement thus far, it is pointless speculating as to how much they paid, and ultimately the cash is less relevant than the deal itself and the long term implications...

With the settlement of the Applera dispute, there is NOT A SINGLE organisation left challenging the validity of GTG's IP. Further, all previous attempts to challenge GTG's patents have failed.

We will no doubt hear shortly, but I would think the deal itself is a great result (regardless of the $$$).

Applera rolled over because they had to. Sure they could easily pay to fight on forever, but given the court's position throughout the case (and a reluctance for US courts to invalidate patents issued in US) , even Applera are probably smart enough to realize a win against GTG was unlikely, and maybe this is cheaper solution for them in the long-run.

In fact Applera are the ones who required limited disclosure to the settlement details, as a prerequisite to settle. (A classic case of 'bully mentality', by a company who loses a battle they asked for, and then doesnt want to be exposed as the loser, when they finally settle).

I think we can assume that after 3 years of money, time and effort, and a market eagerly awaiting closure on this matter, that Merv wouldnt have settled unless it was a positive result in all aspects - cash, cross licences, IP, supply agreements, reagents etc etc etc.

Add to that the kudos of winning against Applera, the validation of GTG's patents again, and a now inevitable influx of biotechs 'who want or need a licence' - and institutions who will want to invest, I would expect that GTG will be overwhelmed with new opportunities and licences, unlike anything we have seen so far.